BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, Montagna L, Piccoli P, Chilosi M, Caligaris-Cappio F. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 2001;97:2777-2783. [PMID: 11313271 DOI: 10.1182/blood.v97.9.2777] [Cited by in Crossref: 246] [Cited by in F6Publishing: 57] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Efremov DG, Wiestner A, Laurenti L. Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL. Mediterr J Hematol Infect Dis 2012;4:e2012067. [PMID: 23170196 DOI: 10.4084/MJHID.2012.067] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
2 Vassallo J, Al Saati T, Gascoyne RD, Welsh K, Reed JC, Brousset P, Delsol G. Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections. J Hematop 2010;3:3-9. [PMID: 21279158 DOI: 10.1007/s12308-009-0054-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Mulder TA, Wahlin BE, Österborg A, Palma M. Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application. Cancers (Basel) 2019;11:E915. [PMID: 31261914 DOI: 10.3390/cancers11070915] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
4 Oppezzo P, Navarrete M, Chiorazzi N. AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression. Front Oncol 2021;11:634383. [PMID: 34041018 DOI: 10.3389/fonc.2021.634383] [Reference Citation Analysis]
5 Orbach A, Rachmilewitz J, Shani N, Isenberg Y, Parnas M, Huang JH, Tykocinski ML, Dranitzki-Elhalel M. CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling. Am J Pathol 2010;177:3159-68. [PMID: 21088216 DOI: 10.2353/ajpath.2010.100301] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
6 Gradowski JF, Sargent RL, Craig FE, Cieply K, Fuhrer K, Sherer C, Swerdlow SH. Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression. Am J Clin Pathol 2012;138:132-9. [PMID: 22706868 DOI: 10.1309/AJCPIVKZRMPF93ET] [Cited by in Crossref: 37] [Cited by in F6Publishing: 4] [Article Influence: 4.6] [Reference Citation Analysis]
7 Robinson JW, Li JY, Walker LD, Tyagi AM, Reott MA, Yu M, Adams J, Weitzmann MN, Pacifici R. T cell-expressed CD40L potentiates the bone anabolic activity of intermittent PTH treatment. J Bone Miner Res 2015;30:695-705. [PMID: 25359628 DOI: 10.1002/jbmr.2394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
8 Gandhi AM, Ben-Ezra JM. Do Bcl-2 and survivin help distinguish benign from malignant B-cell lymphoid aggregates in bone marrow biopsies? J Clin Lab Anal 2004;18:285-8. [PMID: 15543568 DOI: 10.1002/jcla.20039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50. [PMID: 19956173 DOI: 10.1038/nrc2764] [Cited by in Crossref: 383] [Cited by in F6Publishing: 326] [Article Influence: 31.9] [Reference Citation Analysis]
10 Do P, Beckwith KA, Cheney C, Tran M, Beaver L, Griffin BG, Mo X, Liu Y, Lapalombella R, Hertlein E, Muthusamy N, Byrd JC. Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells. J Immunol 2019;202:2806-16. [PMID: 30910862 DOI: 10.4049/jimmunol.1801359] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
11 Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, Nefzi A, Reed JC, Pinilla C, Kipps TJ. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 2005;106:1742-8. [PMID: 15914559 DOI: 10.1182/blood-2005-02-0695] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
12 El-Daly SM, Bayraktar R, Anfossi S, Calin GA. The Interplay between MicroRNAs and the Components of the Tumor Microenvironment in B-Cell Malignancies. Int J Mol Sci 2020;21:E3387. [PMID: 32403283 DOI: 10.3390/ijms21093387] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
13 Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, Fenlon M, Rassenti L, Cottam H, Kipps TJ, Insel PA. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2008;105:19532-7. [PMID: 19033455 DOI: 10.1073/pnas.0806152105] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
14 Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011;17:2977-2986. [PMID: 21402714 DOI: 10.1158/1078-0432.ccr-10-2879] [Cited by in Crossref: 91] [Cited by in F6Publishing: 47] [Article Influence: 9.1] [Reference Citation Analysis]
15 Sugahara K, Uemura A, Harasawa H, Nagai H, Hirakata Y, Tomonaga M, Murata K, Sohda H, Nakagoe T, Shibasaki S, Yamada Y, Kamihira S. Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. Int J Hematol 2004;80:52-8. [PMID: 15293568 DOI: 10.1532/ijh97.04031] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
16 Scielzo C, Ghia P. Modeling the Leukemia Microenviroment In Vitro. Front Oncol 2020;10:607608. [PMID: 33392097 DOI: 10.3389/fonc.2020.607608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
17 Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Andreeff M, Goodell MA, Heslop HE, Brenner MK. Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer 2009;8:106. [PMID: 19922650 DOI: 10.1186/1476-4598-8-106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Ghamlouch H, Ouled-Haddou H, Guyart A, Regnier A, Trudel S, Claisse JF, Fuentes V, Royer B, Marolleau JP, Gubler B. Phorbol myristate acetate, but not CD40L, induces the differentiation of CLL B cells into Ab-secreting cells. Immunol Cell Biol 2014;92:591-604. [PMID: 24797583 DOI: 10.1038/icb.2014.37] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
19 Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, Murphy EJ, Koduru P, Ferrarini M, Zupo S, Cutrona G, Damle RN, Wasil T, Rai KR, Hellerstein MK, Chiorazzi N. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755-64. [PMID: 15711642 DOI: 10.1172/JCI23409] [Cited by in Crossref: 398] [Cited by in F6Publishing: 175] [Article Influence: 24.9] [Reference Citation Analysis]
20 Ding W, Knox TR, Tschumper RC, Wu W, Schwager SM, Boysen JC, Jelinek DF, Kay NE. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010;116:2984-93. [PMID: 20606160 DOI: 10.1182/blood-2010-02-269894] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
21 Herman SE, Wiestner A. Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade. Semin Oncol 2016;43:222-32. [PMID: 27040700 DOI: 10.1053/j.seminoncol.2016.02.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
22 Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-899. [PMID: 20303878 DOI: 10.1016/j.cell.2010.01.025] [Cited by in Crossref: 5767] [Cited by in F6Publishing: 5024] [Article Influence: 524.3] [Reference Citation Analysis]
23 Hanna BS, Roessner PM, Yazdanparast H, Colomer D, Campo E, Kugler S, Yosifov D, Stilgenbauer S, Schmidt M, Gabriel R, Lichter P, Seiffert M. Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia 2019;33:625-37. [PMID: 30267008 DOI: 10.1038/s41375-018-0250-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 12.3] [Reference Citation Analysis]
24 Ciszak L, Frydecka I, Wolowiec D, Szteblich A, Kosmaczewska A. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody. Tumour Biol 2016;37:4143-57. [PMID: 26490985 DOI: 10.1007/s13277-015-4217-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
25 Benkisser-Petersen M, Buchner M, Dörffel A, Dühren-von-Minden M, Claus R, Kläsener K, Leberecht K, Burger M, Dierks C, Jumaa H, Malavasi F, Reth M, Veelken H, Duyster J, Zirlik K. Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia. PLoS One 2016;11:e0169159. [PMID: 28036404 DOI: 10.1371/journal.pone.0169159] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Damle RN, Calissano C, Chiorazzi N. Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol 2010;23:33-45. [PMID: 20620969 DOI: 10.1016/j.beha.2010.02.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
27 Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Goodell MA, Heslop HE, Brenner MK. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia 2010;24:563-72. [PMID: 20072155 DOI: 10.1038/leu.2009.281] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
28 Burger JA, Quiroga MP, Hartmann E, Bürkle A, Wierda WG, Keating MJ, Rosenwald A. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009;113:3050-8. [PMID: 19074730 DOI: 10.1182/blood-2008-07-170415] [Cited by in Crossref: 216] [Cited by in F6Publishing: 201] [Article Influence: 16.6] [Reference Citation Analysis]
29 Zhuang J, Laing N, Oates M, Lin K, Johnson G, Pettitt AR. Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis. Pharmacol Res Perspect 2014;2:e00081. [PMID: 25505620 DOI: 10.1002/prp2.81] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
30 Caligaris-Cappio F. Inflammation, the microenvironment and chronic lymphocytic leukemia. Haematologica 2011;96:353-5. [PMID: 21357715 DOI: 10.3324/haematol.2010.039446] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
31 Purroy N, Wu CJ. Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med 2017;7:a026740. [PMID: 28096240 DOI: 10.1101/cshperspect.a026740] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
32 Foster AE, Brenner MK, Dotti G. Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2008;21:375-89. [PMID: 18790444 DOI: 10.1016/j.beha.2008.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
33 Sengupta S, Nandi S, Hindi ES, Wainwright DA, Han Y, Lesniak MS. Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia 2010;12:837-47. [PMID: 20927322 DOI: 10.1593/neo.10662] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
34 Packham G, Krysov S, Allen A, Savelyeva N, Steele AJ, Forconi F, Stevenson FK. The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica 2014;99:1138-48. [PMID: 24986876 DOI: 10.3324/haematol.2013.098384] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 10.8] [Reference Citation Analysis]
35 Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood 2010;116:1083-91. [PMID: 20442367 DOI: 10.1182/blood-2009-10-246199] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
36 Herishanu Y, Katz BZ, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am 2013;27:173-206. [PMID: 23561469 DOI: 10.1016/j.hoc.2013.01.002] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
37 Gutjahr JC, Greil R, Hartmann TN. The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia. Front Immunol 2015;6:177. [PMID: 25941526 DOI: 10.3389/fimmu.2015.00177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
38 Ghosh AK, Kay NE, Secreto CR, Shanafelt TD. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res 2009;15:1250-8. [PMID: 19228728 DOI: 10.1158/1078-0432.CCR-08-1511] [Cited by in Crossref: 86] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
39 Kostareli E, Gounari M, Agathangelidis A, Stamatopoulos K. Immunoglobulin gene repertoire in chronic lymphocytic leukemia: insight into antigen selection and microenvironmental interactions. Mediterr J Hematol Infect Dis 2012;4:e2012052. [PMID: 22973496 DOI: 10.4084/MJHID.2012.052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
40 Cerutti A, Zan H, Kim EC, Shah S, Schattner EJ, Schaffer A, Casali P. Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells. J Immunol 2002;169:6594-603. [PMID: 12444172 DOI: 10.4049/jimmunol.169.11.6594] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
41 Packham G, Stevenson FK. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 2005;114:441-9. [PMID: 15804279 DOI: 10.1111/j.1365-2567.2005.02117.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 94] [Article Influence: 6.4] [Reference Citation Analysis]
42 Martinez A, Bellosillo B, Bosch F, Ferrer A, Marcé S, Villamor N, Ott G, Montserrat E, Campo E, Colomer D. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol. 2004;164:501-510. [PMID: 14742256 DOI: 10.1016/S0002-9440(10)63140-9] [Cited by in Crossref: 76] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
43 Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntañola A, Abrisqueta P, Rozman M, Rozman C, Bosch F, Campo E, Montserrat E. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010;95:1526-33. [PMID: 20421272 DOI: 10.3324/haematol.2010.022277] [Cited by in Crossref: 111] [Cited by in F6Publishing: 88] [Article Influence: 10.1] [Reference Citation Analysis]
44 Ghamlouch H, Ouled-Haddou H, Damaj G, Royer B, Gubler B, Marolleau JP. A combination of cytokines rescues highly purified leukemic CLL B-cells from spontaneous apoptosis in vitro. PLoS One. 2013;8:e60370. [PMID: 23555960 DOI: 10.1371/journal.pone.0060370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
45 De Cecco L, Capaia M, Zupo S, Cutrona G, Matis S, Brizzolara A, Orengo AM, Croce M, Marchesi E, Ferrarini M, Canevari S, Ferrini S. Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells. PLoS One 2015;10:e0134706. [PMID: 26305332 DOI: 10.1371/journal.pone.0134706] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
46 Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, Sison C, Allen SL, Rai KR, Chiorazzi N. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007;110:3352-9. [PMID: 17684154 DOI: 10.1182/blood-2007-04-083832] [Cited by in Crossref: 113] [Cited by in F6Publishing: 98] [Article Influence: 8.1] [Reference Citation Analysis]
47 Fecteau JF, Kipps TJ. Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed) 2012;4:61-73. [PMID: 22202043 DOI: 10.2741/251] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
48 Walsby E, Pearce L, Burnett AK, Fegan C, Pepper C. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget 2012;3:525-34. [PMID: 22619113 DOI: 10.18632/oncotarget.491] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
49 Dubois N, Crompot E, Meuleman N, Bron D, Lagneaux L, Stamatopoulos B. Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles. Front Oncol 2020;10:1422. [PMID: 32974152 DOI: 10.3389/fonc.2020.01422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
50 Wang JQ, Jeelall YS, Ferguson LL, Horikawa K. Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation. Front Immunol 2014;5:367. [PMID: 25132836 DOI: 10.3389/fimmu.2014.00367] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 9.3] [Reference Citation Analysis]
51 Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR, Chen W. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 2010;115:5041-52. [PMID: 20339095 DOI: 10.1182/blood-2009-03-213363] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.0] [Reference Citation Analysis]
52 Liu X, Long Z, Cai H, Yu S, Wu J. TRIM58 suppresses the tumor growth in gastric cancer by inactivation of β-catenin signaling via ubiquitination. Cancer Biol Ther 2020;21:203-12. [PMID: 31747856 DOI: 10.1080/15384047.2019.1679554] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
53 Ghamlouch H, Ouled-Haddou H, Guyart A, Regnier A, Trudel S, Claisse JF, Fuentes V, Royer B, Marolleau JP, Gubler B. TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells. Front Immunol 2014;5:292. [PMID: 24982661 DOI: 10.3389/fimmu.2014.00292] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
54 García-Muñoz R, Roldan Galiacho V, Llorente L. Immunological aspects in chronic lymphocytic leukemia (CLL) development. Ann Hematol 2012;91:981-96. [PMID: 22526361 DOI: 10.1007/s00277-012-1460-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
55 Davids MS, Brown JR. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:2362-70. [PMID: 22616724 DOI: 10.3109/10428194.2012.695781] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
56 Luqman M, Klabunde S, Lin K, Georgakis GV, Cherukuri A, Holash J, Goldbeck C, Xu X, Kadel EE 3rd, Lee SH, Aukerman SL, Jallal B, Aziz N, Weng WK, Wierda W, O'Brien S, Younes A. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112:711-20. [PMID: 18497318 DOI: 10.1182/blood-2007-04-084756] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 6.2] [Reference Citation Analysis]
57 Purroy N, Abrisqueta P, Carabia J, Carpio C, Calpe E, Palacio C, Castellví J, Crespo M, Bosch F. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia 2014;28:1993-2004. [PMID: 24618734 DOI: 10.1038/leu.2014.96] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]